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ABSTRACT
Objective We hypothesised that, compared with
culprit-only primary percutaneous coronary intervention
(PCI), additional preventive PCI in selected patients with
ST-elevation myocardial infarction with multivessel
disease would not be associated with iatrogenic
myocardial infarction, and would be associated with
reductions in left ventricular (LV) volumes in the longer
term.
Methods In the preventive angioplasty in myocardial
infarction trial (PRAMI; ISRCTN73028481), cardiac
magnetic resonance (CMR) was prespeciﬁed in two
centres and performed (median, IQR) 3 (1, 5) and 209
(189, 957) days after primary PCI.
Results From 219 enrolled patients in two sites, 84%
underwent CMR. 42 (50%) were randomised to culprit-
artery-only PCI and 42 (50%) were randomised to
preventive PCI. Follow-up CMR scans were available in
72 (86%) patients. There were two (4.8%) cases of
procedure-related myocardial infarction in the preventive
PCI group. The culprit-artery-only group had a higher
proportion of anterior myocardial infarctions (MIs) (55%
vs 24%). Infarct sizes (% LV mass) at baseline and
follow-up were similar. At follow-up, there was no
difference in LV ejection fraction (%, median (IQR),
(culprit-artery-only PCI vs preventive PCI) 51.7 (42.9,
60.2) vs 54.4 (49.3, 62.8), p=0.23), LV end-diastolic
volume (mL/m2, 69.3 (59.4, 79.9) vs 66.1 (54.7, 73.7),
p=0.48) and LV end-systolic volume (mL/m2, 31.8 (24.4,
43.0) vs 30.7 (23.0, 36.3), p=0.20). Non-culprit
angiographic lesions had low-risk Syntax scores and
47% had non-complex characteristics.
Conclusions Compared with culprit-only PCI,
non-infarct-artery MI in the preventive PCI strategy was
uncommon and LV volumes and ejection fraction were
similar.
INTRODUCTION
Patients with acute ST-elevation myocardial infarc-
tion (STEMI) and multivessel coronary artery
disease have an increased risk of adverse out-
comes,1 2 however, the optimal management of
non-culprit lesions is controversial. Following
primary percutaneous coronary intervention (PCI),
additional PCI of non-culprit-artery lesions might
prevent recurrent ischaemia and adverse cardiac
events.1 2 On the other hand, it may cause compli-
cations, including iatrogenic myocardial infarction
secondary to the PCI procedure through coronary
microembolisation leading to a larger overall infarct
burden.3 4 Evidence of harm associated with non-
culprit-artery PCI in large registries5 6 and systematic
reviews7 underpins the caution in current guideline
recommendations regarding routine PCI of non-
culprit-artery lesions during primary PCI.8–10
In the randomised trial of preventive angioplasty in
myocardial infarction (PRAMI; ISRCTN7302848111),
immediate preventive PCI of angiographically signiﬁ-
cant non-culprit-artery stenoses in 465 patients with
STEMI and multivessel disease reduced the inci-
dence of the composite primary outcome (cardiac
death, non-fatal myocardial infarction (MI), refrac-
tory angina) by 14% at 2 years.
Similar results have recently been reported in the
complete versus culprit lesion-only PRimary PCI
trial (CvLPRIT) (ISRCTN70913605) trial,12 but in
the DANAMI-3-PRIMULTI trial the beneﬁt of
complete revascularisation was driven by signiﬁ-
cantly fewer repeat revascularisations, because all-
cause mortality and non-fatal reinfarction did not
differ between groups.13 Taken together, the rela-
tive risk reduction of the primary composite
outcome in these three trials ranges from 45% to
65%.11–13 On the other hand, these trials were not
powered to assess cardiac mortality and the per-
formance and timing of non-culprit vessel PCI after
primary PCI remains an open and controversial
question. In 203 patients in the culprit cardiac mag-
netic resonance (CMR) substudy there was a statis-
tically signiﬁcant increase in non-infarct-related
artery MI in the complete revascularisation group
but total infarct size was not signiﬁcantly different
compared with an infarct related artery (IRA) only
strategy.14 Speciﬁcally, questions still remain about
the risk of iatrogenic MI secondary to the add-
itional PCI procedures increasing infarct size
overall, and the associations between non-culprit
PCI and left ventricular (LV) ejection fraction and
volumes in the longer term.
We hypothesised that, compared with culprit-
only primary PCI, additional preventive PCI in
selected STEMI patients with multivessel disease
would (1) not be associated with iatrogenic myocar-
dial infarction secondary to the preventive PCI pro-
cedures and (2) would have a similar infarct size.
CMR is the reference diagnostic imaging method
for the assessment of infarct size15 and LV
volumes.16 In a prespeciﬁed CMR substudy, we
prospectively assessed infarct size and LV volumes.
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CMR has potential to be clinically useful for the assessment of
procedure-related MI, which cannot otherwise be reliably
detected using a troponin elevation or the electrocardiogram in
the setting of acute STEMI.
METHODS
Setting
The PRAMI CMR substudy took place in the Golden Jubilee
National Hospital, Clydebank and the Freeman Hospital,
Newcastle. Both of these hospitals are regional cardiac centres.
Acute STEMI management follows contemporary guidelines.
Aspiration thrombectomy, direct stenting, antithrombotic drugs
and other therapies were administered according to clinical
judgement and in line with the guidelines.8–10 Further details
are available in the online supplement.
CMR acquisition
CMR scans were performed during the index hospitalisation
within (median, IQR) 3 (1, 5) days post-randomisation and
repeated 209 (189, 957) days after primary PCI.
CMR methods
CMR image acquisition
Information about MRI acquisition is provided in the online
supplement.
CMR image analysis
Image analysis was performed using a core laboratory with dedi-
cated CMR software (Siemens Syngo VE32D and Argus,
Erlangen, Germany). CMR data were anonymised and then ana-
lysed in a random order by a CMR-trained cardiologist (KM)
who was blinded to the treatment group assignment and all
other clinical and health outcome data. Image quality was
assessed using Likert scale quality scores.
Infarct deﬁnition and size
The myocardial mass of late gadolinium was quantiﬁed using
computer-assisted planimetry as a hyperintense region over ﬁve
SDs the signal intensity of remote (see online supplement).
Adverse remodelling
Adverse remodelling was deﬁned as an increase in LV end-
diastolic volume and end-systolic volume ≥20% on the
follow-up CMR scan versus baseline early post-MI.
Non-infarct-related artery infarcts
Areas of non-infarct-artery late gadolinium enhancement were
additionally classiﬁed as likely to be acute or chronic based on
the presence of myocardial wall thickness (reduced (thinned)
versus increased (thick/swollen) and oedema (yes/no) on
T2-weighted sequences. This was done by two observers (KM
and CB). T2-weighted CMR was not used to assess the
area-at-risk as two sequences: a bright-blood T2-weighted
ACUT2E method (acquisition for cardiac uniﬁed T2 oedema)17
and a T2 mapping method using an investigational prototype
were used during the length of this study.
Quantitative coronary analysis
The coronary angiograms underwent quantitative coronary ana-
lysis (QCA) of culprit and non-culprit lesions. The analyses
were performed by an interventional cardiologist (BWH) who
was blinded to the CMR and who had not been involved in any
other aspect of the study. The QCA analyses were performed on
a Centricity CA 1000 Cardiac Review 1.0 workstation (GE
Healthcare, Buckinghamshire, UK).
Statistical analysis
The primary outcome was the change in LV end-systolic volume
index (mL/m2) revealed by CMR at follow-up versus baseline. A
prioritised secondary outcome was the occurrence of myocardial
infarction in the territory of a non-culprit lesion treated by pre-
ventive PCI (ie, iatrogenic myocardial infarction) (see online
supplementary material methods).
Sample size calculation
For a between-group treatment difference of 3.0 mL/m2 for the
within-subject change in LV end-systolic volume index at
follow-up versus baseline and an SD of 4.5 mL/m2 then 37 sub-
jects with evaluable data would be required in each group to
refute the null hypothesis of no difference with 80% power and
a two-sided test of signiﬁcance level (α=0.05).
Data analysis
Categorical variables were expressed as number and percentage
of patients. Categorical variables were analysed using a χ2 test,
or a Fisher’s exact test if any of the expected cell sizes were <5.
Most continuous variables had a skewed distribution and are
therefore presented as median and IQR, and analysed using
Mann-Whitney statistical tests. Statistical analysis was not
carried out on baseline characteristics as per the CONSORT
statement recommendation.18
We also carried out a multivariate regression analysis model,
adjusting log-corrected total infarct size between groups for MI
location (anterior vs non-anterior), time to reperfusion, age of
participants at presentation, thrombolysis in myocardial infarc-
tion (TIMI) score (pre-PCI), Rentrop score (pre-PCI) and dia-
betes mellitus status.
A p value <0.05 was taken as signiﬁcant. The statistical
packages used in the analysis were R V.2.15 (http://www.
r-project.org) and Minitab 17 (http://www.minitab.com).
RESULTS
Patient characteristics
Of 465 subjects enrolled in six sites in the PRAMI trial, 219
(47%) were enrolled in two hospitals in Glasgow and
Newcastle. Of these, 84 (38%) participants (mean age 60.4 SD
11.1 years, 77% male) (table 1) underwent CMR at baseline
during the ﬁrst week post-MI. Figure 1 illustrates the ﬂow
diagram of the randomised participants, including the reasons
for not undergoing CMR.
The participants were evenly distributed between the rando-
mised groups (n=42 (50%) culprit-artery-only PCI; n=42
(50%) preventive PCI). The time from symptom onset to PCI
was longer in the culprit-only group (average time 330
±332 min) than in the preventive PCI group (273±248 min)
but this difference was not statistically signiﬁcant (p=0.38).
Their clinical characteristics are described in table 1.
Angiographic ﬁndings
The Syntax scores of the randomised participants were consist-
ent with non-complex coronary disease (table 2). The Syntax
and APPROACH scores and the American Heart Association
classiﬁcation of lesion complexity were similar in both groups.
Preventive PCI reduced the angiographic burden of disease
and extent of myocardial jeopardy, as revealed by the post-PCI
Syntax and APPROACH scores, respectively (table 2).
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CMR ﬁndings
At baseline, 80 (95%) of the cine imaging, and 73 (87%) of late
gadolinium enhancement (LGE) imaging were of high quality.
At follow-up, 68 (94%) of the cine imaging, and 68 (94%) of
the LGE imaging were of high quality. At baseline 2 (2%) of the
T2 weighted imaging and LGE were missing (see online supple-
mentary table S1).
LV ejection fraction and volumes, and remodelling were
similar in each of the randomised groups at baseline and
follow-up (table 3; see online supplementary table S2). The
timing of CMR was similar between the groups (table 3; see
online supplement).
The primary outcome (cardiac death, non-fatal MI and
refractory angina) had occurred in four participants assigned to
preventive PCI and in seven participants assigned to
culprit-artery-only PCI (table 4).
Infarct size and distribution revealed by late gadolinium
enhancement imaging were similar in each of the randomised
groups at baseline and at follow-up (table 3). Two patients did
not have late gadolinium enhancement acquisitions. One of the
patients randomised to culprit-artery-only PCI had an eGFR
<30 mL/min/1.73 m2 and thus IV gadolinium contrast agent
was not administered. One of the patients randomised to pre-
ventive PCI could not tolerate the CMR scan, so scanning was
terminated after acquisition of the cine sequences.
On multivariate regression analysis, there was still no signiﬁ-
cant difference in infarct size between patients randomised to
preventive PCI and culprit-artery-only PCI (p=0.74). Using the
same model approach but with log-transformed infarct-artery
infarct size instead of total infarct size, this model yielded a
between-group p value of 0.95.
On the baseline CMR scans, four patients randomised to pre-
ventive PCI had evidence of late gadolinium enhancement in
the territory of a non-culprit-artery treated by PCI (table 3;
ﬁgure 2). In two of these cases, this abnormality was associated
with myocardial wall thinning on cine acquisitions and thus
these infarcts were considered chronic. The two patients rando-
mised to culprit-artery-only PCI who had evidence of remote
zone scar did not have oedema on T2-weighted imaging, and
on cine acquisitions had the myocardium was thinned. These
abnormalities were considered to be chronic infarction.
DISCUSSION
The main ﬁndings in the PRAMI CMR substudy were that, in
line with our ﬁrst hypothesis, the incidence of iatrogenic myo-
cardial infarction in the preventive PCI group was uncommon
(4.8%), and appears to be lower than the incidence of
non-infarct-artery MI (17%) in the population of patients who
underwent CMR in the CvLPRIT trial.14 Infarct size was similar
between groups within the ﬁrst week after randomisation, even
Table 1 Characteristics of the PRAMI participants and participants in the CMR substudy
Characteristics PRAMI preventive CMR substudy preventive PRAMI culprit only CMR substudy culprit only
Number of participants 234 42 231 42
Mean age (range), years 62 (32–92) 61 (38–89) 62 (33–90) 60 (39–83)
Male 177 (76) 31 (74) 186 (81) 34 (81)
Female 57 (24) 11 (26) 45 (19) 9 (21)
Medical history, n (%)
Diabetes 35 (15) 5 (12) 48 (21) 3 (7)
Hypertension 94 (40) 10 (24) 93 (40) 11 (26)
Smoker 118 (50) 31 (74) 103 (45) 26 (62)
Previous stroke 10 (4) 0 (0) 10 (4) 0 (0)
Previous myocardial infarction 19 (8) 0 (0) 16 (7) 1 (2)
Blood pressure, mm Hg*
Systolic 136 (26) 143 (24) 134 (26) 142 (29)
Diastolic 81 (14) 81 (13) 80 (15) 85 (17)
ST-elevation location, n (%)
Anterior 67 (29) 10 (24) 89 (39) 23 (55)
Inferior 154 (66) 28 (67) 128 (55) 15 (36)
Lateral 10 (4) 1 (2) 14 (6) 2 (5)
Coronary arteries with stenosis, n (%)
2 143 (61) 33 (79) 155 (67) 30 (71)
3 91 (39) 9 (21) 76 (33) 121 (29)
Infarct artery, number of stents*
Infarct artery* 1.56 (0.75) 1.51 (0.60) 1.42 (0.70) 1.41 (0.63)
Non-infarct artery* 1.36 (0.77) 1.38 (0.55) NA NA
Medical therapy, n (%)
Use of glycoprotein IIb/IIIa 178 (76) 35 (83) 176 (76) 39 (93)
Aspirin 233 (100) 42 (100) 229 (100) 42 (100)
Clopidogrel 234 (100) 42 (100) 229 (100) 42 (100)
Statin 222 (95) 40 (95) 223 (97) 39 (93)
β-blocker 207 (88) 37 (88) 210 (92) 36 (86)
ACE inhibitor or angiotensin-receptor blocker 218 (93) 39 (93) 209 (91) 36 (86)
The distribution of clinical characteristics was similar between the randomised groups (p>0.05) for all comparisons.
*Mean (SD).
CMR, cardiac magnetic resonance; PRAMI, preventive angioplasty in myocardial infarction.
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after adjustment for confounders. Second, LV volumes and
ejection fraction were similar acutely and in the longer
term, suggesting that differences in LV remodelling are unlikely
to explain the beneﬁts of preventive PCI observed in the
PRAMI trial.
Strengths and limitations of the current study and results
The strengths of our study include the use of multimodality
CMR to assess infarct characteristics, including non-infarct-
artery MI and LV remodelling.19 Second, the CMR substudy
participants represented one-third of the PRAMI trial popula-
tion in the participating centres, and their clinical characteristics
were broadly similar to those of the overall trial population.11
As in the main trial, by chance, anterior myocardial infarction
was more common in the infarct-artery-only PCI group. On the
other hand, the APPROACH Lesion Score for myocardial jeop-
ardy, and coronary plaque characteristics, were similar between
the groups. The comparatively long duration of follow-up was
intended to align with that of the overall trial and thus reﬂect
longer-term changes in infarct size and LV remodelling. We also
assessed clinical characteristics associated with PCI-related com-
plications20–22 (table 1).
The main limitation of our study is the sample size. The study
is underpowered to detect between-group differences in LV end-
systolic volume (<3.0 mL/m2), LV ejection fraction and infarct
size. We used oedema imaging qualitatively to identify areas of
acute injury, however, we did not quantify the area-at-risk and
myocardial salvage index, as two different T2-weighted
sequences were used during the course of the study (see online
supplement). CMR information on deceased patients was
lacking.
Insights into the potential beneﬁt of preventive PCI
The LV volumes and ejection fraction in the surviving patients
who completed CMR follow-up were similar in each of the
groups. While a type 2 error is not discounted, these CMR
results support the possibility that the beneﬁt of the immediate
preventive PCI strategy in PRAMI may be mediated by preven-
tion of recurrent spontaneous cardiac events by immediate PCI,
in line with the main results of PRAMI11 and CvLPRIT.12 Our
Figure 1 CONSORT ﬂow diagram depicting the PRAMI CMR substudy. A total of 219 patients were enrolled in Glasgow and Newcastle and 84 of
these patients gave informed consent to participate in the CMR substudy. CMR, cardiac magnetic resonance; PCI, percutaneous coronary
intervention; PRAMI, preventive angioplasty in myocardial infarction.
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Table 2 Coronary artery plaque characteristics revealed by invasive angiography in the PRAMI participants
Culprit-artery-only PCI Preventive PCI p Value
Pre-PCI* n=42 n=42
Time to reperfusion (minutes) median, IQR 174 (129, 413) 177 (123, 326) 0.20
Syntax score pre-PCI 17.75 (12.00, 25.75) 13.00 (10.00, 21.00) 0.09
APPROACH score (QCA) pre-PCI 50.73 (31.28, 63.00) 39.60 (27.75, 58.03) 0.09
AHA classification-simple lesions (A, B1), n (%) 18 (25%) 18 (25%) 1.00
Culprit lesions* n=43† n=42
Complex lesion, n (%) 41 (95%) 42 (100%)
Median QCA stenosis ratio (% diameter) 100.00 (65.14, 100.00) 100.00 (78.85, 100) 0.16
Lesion length (mm) 11.66 (9.48, 14.38) 13.64 (8.63, 17.72) 0.353
APPROACH score (QCA) 27.75 (18.50, 44.50) 27.50 (18.50, 28.24) 0.12
Non-culprit lesions* n=56 n=54
Complex lesion, n (%) 21 (38%) 31 (57%)
Median QCA stenosis ratio (% diameter) 59.53 (51.66, 78.68) 56.31 (48.92, 65.20) 0.06
Lesion length (mm) 10.43 (7.14, 13.74) 10.48 (7.66, 15.29) 0.632
APPROACH score (QCA) 18.50 (0.00, 27.75) 15.25 (0.00, 29.70) 0.68
Post-PCI* n=42 n=42
Intraprocedural thrombotic events n (%) 6 (14) 9 (21) 0.754
Syntax score, post-PCI 4.00 (3.00, 7.25) 0.00 (0.00, 0.00) <0.001
APPROACH score (QCA) 18.50 (0.00, 27.75) 0.00 (0.00, 0.00) <0.001
*Continuous data are summarised by median (IQR); Mann-Whitney test for continuous data, χ2 for categorical variables.
†One patient in the culprit-only group had two culprit lesions in the same coronary artery.
AHA, American Heart Association; PCI, percutaneous coronary intervention; PRAMI, preventive angioplasty in myocardial infarction; QCA, quantitative coronary analysis.
Table 3 Baseline and follow-up CMR
Culprit-artery-only PCI Preventive PCI p Value
CMR at baseline, n=84* n=42 n=42
LV ejection fraction, %† 47.9 (40.3, 47.9) 48.5 (38.6, 55.8) 0.96
LV end-diastolic volume index, mL/m2† 64.8 (57.1, 77.4) 68.5 (54.7, 79.0) 0.86
LV end-systolic volume index, mL/m2† 33.5 (27.3, 47.8) 34.1 (25.5, 49.1) 0.92
Total infarct size (% LVM)*‡ n=41 n=41
Median (IQR) 15.66 (6.18, 28.78) 14.62 (4.81, 20.10) 0.33
Mean (SD) (18.12 (13.85)) (14.83 (11.75)) –
Time from PPCI (days), mean (range) 5 (0–32) 4 (1–14) 0.41
Infarct on LGE, n (%) 37 (90) 39 (95) 0.67
Microvascular obstruction, n (%) 10 (24) 8 (20) 0.60
Microvascular obstruction, % LV mass† 0.00 (0.00, 0.60)
range (0.00:0.28)
0.00 (0.00, 0.00)
range (0.00:0.15)
0.64
Infarct in non-infarct-related artery territory, n (%) 2 (5) 4 (10) 0.68
Acute infarct in non-infarct-related artery territory, n (%) 0 (0) 2 (5) 0.15
Culprit-artery infarct size (% LVM) irrespective of acute or chronic§
Median (IQR) 15.66 (6.18, 28.78) 13.25 (3.87, 17.85) 0.16
Mean (SD) (17.91 (13.91)) (13.55 (11.60)) –
Non-culprit-artery infarct size (% LVM)
Mean±SD 4.34±0.79 9.70±4.41 0.11
Follow-up CMR n=37 n=35
Time to CMR (days), median (IQR) 210 (195, 994) 209 (186, 419) 0.42
Total infarct size (% LVM)‡
Median (IQR) 13.43 (3.30, 22.15) 7.68 (2.10, 12.09) 0.14
Infarct on LGE, n (%) 35 (95) 32 (91) 0.66
Patients with >1 infarct, n (%) 4 (11) 5 (14) 0.73
Adverse remodelling, n (%) 4 (10) 7 (17) 0.52
LV ejection fraction, %† 51.7 (42.9, 60.2) 54.4 (49.3, 62.8) 0.23
LV end-diastolic volume index, mL/m2† 69.3 (59.4, 79.9) 66.1 (54.7, 73.7) 0.48
LV end-systolic volume index, mL/m2† 31.8 (24.4, 43.0) 30.7 (23.0, 36.3) 0.20
*One of the patients randomised to culprit-artery-only PCI had an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 and thus IV gadolinium contrast agent was not
administered. One of the patients randomised to preventive PCI could not tolerate the CMR scan, scanning was terminated after acquisition of cine sequences. % LVM (% left ventricular mass).
†Mean (SD) or median (IQR).
‡Total infarct size includes both acute and chronic infarcts.
§Acute infarct size adjusted (age, anterior MI, TIMI pre-coronary intervention, time to reperfusion, diabetes mellitus (DM), Rentrop) gives a p value of 0.735 comparing culprit-artery-only PCI with
preventive PCI.
CMR, cardiac magnetic resonance; LV, left ventricular; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention.
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results are uniformly consistent with those observed in the
larger CvLPRIT CMR substudy14 that involved 205 randomised
participants. In that study, as in our own, there were no
between-group difference in LV volumes and ejection fraction
or infarct size, on baseline and follow-up CMR.23 24 Missing
CMR data from deceased patients are a relevant gap since one
mechanism of beneﬁt of preventive PCI may be prevention of
fatal MI and cardiac death.
Importance of the timing of enrolment and randomisation:
before versus after culprit-artery PCI and relevance to
clinical practice
Based on our angiographic analysis, the non-culprit lesions had
low-risk Syntax scores and 47% had non-complex characteristics
(table 2), implying selection of lower risk lesions for immediate
preventive PCI. In PRAMI, participant eligibility was based on
the presence of non-culprit lesions that were deemed by the car-
diologist to be amenable to PCI and therefore enrolment after
successful culprit-artery PCI was at operator discretion. In other
words, preventive PCI was performed in patients in whom the
operator believed additional immediate PCI would be feasible,
safe and successful. The 4.8% incidence of iatrogenic MI in the
preventive PCI group in our PRAMI CMR study was lower than
Table 4 Prespecified adverse clinical outcomes in the CMR
substudy participants
Characteristic
Culprit-artery-only
PCI
n=42 (50%)
Preventive
PCI
n=42 (50%)
Primary outcome*
Death from cardiac causes, non-fatal
myocardial infarction or refractory
angina
7 4
Death from cardiac causes or
non-fatal myocardial infarction
4 2
Death from cardiac causes 2 0
Non-fatal myocardial infarction 2 2
Refractory angina 3 2
Secondary outcomes*
Death from non-cardiac causes 2 2
Repeat revascularisation 4 3
In line with the preventive angioplasty in myocardial infarction (PRAMI) protocol11 the
study participants underwent standard care follow-up led by the attending physician.
Routine stress testing was not performed and instead stress tests and repeat
revascularisation during follow-up were clinically indicated based on a history of
angina in line with contemporary guidelines.
*The follow-up interval is from randomisation to 1 December 2015.
CMR, cardiac magnetic resonance; PCI, percutaneous coronary intervention.
Figure 2 Late gadolinium enhancement imaging of preventive angioplasty in myocardial infarction (PRAMI) cardiac magnetic resonance (CMR)
substudy participants depicting non-culprit-artery infarcts, with corresponding end-diastolic cine frame. Red crosses indicate culprit-artery-territory
infarct; blue crosses indicate non-culprit-artery-territory infarct. Preventive percutaneous coronary intervention (PCI): (A, B) patient with lateral ST
elevation on ECG underwent PCI to the circumﬂex and to the mid-left anterior descending coronary artery (LAD). Late enhancement revealed an
additional region of scar in the anteroseptal wall. (C, D) Participant with an inferior ST-elevation myocardial infarction (STEMI) with PCI to the right
coronary artery (RCA) underwent CMR which revealed an additional infarct in the anterolateral region. This patient underwent PCI to all three
coronary arteries. (E, F) This patient had PCI to the RCA for an inferior STEMI and PCI to the circumﬂex artery. Late enhancement revealed a small
focus of scarring in the basal anterolateral segment. (G, H) Inferior STEMI with PCI to the culprit RCA and additional PCI to the circumﬂex. Late
enhancement revealed a small infarct in the basal anterolateral segment. Culprit-artery-only PCI: (I, J) participant presented with an anterior STEMI.
Late gadolinium enhancement revealed additional inferolateral infarct. (K, L) Anterior STEMI, with late enhancement in the anteroseptal region and
an additional area in the anterolateral segment.
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in other reports23 24 (eg, 12% incidence of iatrogenic MI in the
CvLPRIT CMR substudy). Importantly, the study design of the
PRAMI11 and CvLPRIT12 trials differed. Based on our CMR
ﬁndings, PRAMI has a low incidence of procedure-related MI,
unlike in CvLPRIT. This difference may be explained by ran-
domisation before culprit-artery PCI in CvLPRIT and so opera-
tors being required by protocol to revascularise lesions that they
might otherwise not have treated on technical grounds (be the
procedure acute or staged within the index admission), implying
higher risk procedures that inevitably would be associated with
a higher risk of complications and procedure-related MI. By
contrast in PRAMI, the protocol invoked the trial intervention
after successful culprit-artery PCI and only in patients who had
an artery amenable to PCI (and that was appropriately inter-
preted to be ‘at that time’). So in PRAMI, there was ﬂexibility to
treat lesions (or not) whereas in CvLPRIT, the operator did not
have that choice. This is further reﬂected in the lower incidence
of microvascular obstruction in our study group (21%) when
compared with other imaging studies in STEMI.14 25 26 This
would suggest that the patient group was lower risk, with an
associated lower event rate. The comparatively low incidence of
microvascular obstruction in our study population may be one
contributing factor for the incidence of adverse health out-
comes, since microvascular obstruction is a complication
post-STEMI that portends an adverse prognosis.27 28
From the perspective of clinical translation to every day prac-
tice, this difference lends support for clinicians to focus on
non-infarct-related artery lesions that are amenable to preventive
PCI and with the decision taking place in the cardiac catheter
laboratory immediately after successful culprit-artery PCI. On
the other hand, patients with higher risk clinical characteristics
or more complex non-infarct-artery disease could be deferred
for staged inpatient revascularisation. We think this strategy
more closely represents how preventive PCI might be adopted
by clinicians in real-life clinical practice.
Clinical relevance of the CMR ﬁndings: contemporary
guidelines and current trials
The guidelines of the European Society of Cardiology on
myocardial revascularisation state that ‘Immediate revasculariza-
tion of signiﬁcant non-culprit lesions during the same procedure
as primary PCI of the culprit vessel may be considered in selected
patients’ (IIb recommendation, Level of Evidence: B).8 The North
American guidelines now have a similar IIb recommendation.10
There are two other clinical trials comparing culprit-only PCI
to complete revascularisation in patients with STEMI and multi-
vessel disease (MVD). The complete versus culprit-only revascular-
isation to treat multivessel disease after primary PCI for STEMI
(COMPLETE; NCT01740479; estimated sample size 3900
patients)29 is designed to assess whether a strategy of complete
revascularisation involving staged PCI of all suitable
non-infarct-related artery lesions is superior to a strategy of culprit
lesion-only revascularisation in reducing the composite outcome of
cardiovascular death or MI in patients with MVD who have
undergone successful culprit lesion primary PCI for STEMI. The
comparison between fractional ﬂow reserve (FFR)-guided revascu-
larisation versus conventional strategy in ACUTE STEMI patients
with MVD (COMPARE-ACUTE; NCT01399736; estimated
sample size 885)30 has broadly similar objectives as COMPLETE,
but is a smaller in scale. These trials should provide meaningful
evidence to inform clinicians and practice guidelines on the
optimal management of STEMI patients with MVD.
LIMITATIONS
The PRAMI CMR substudy involved a limited proportion of
the total number of participants in the main trial PRAMI trial,
reﬂecting the fact that two of the six centres participated in the
CMR study. Further studies are warranted. The distributions of
some of the characteristics of participants in the substudy, for
example, anterior infarct location, departs from those of the
main trial population. The number of clinical events in the sub-
study is lower than in the main trial. Because of changes in the
availability of oedema imaging methods, two T2-weighted
CMR methods were used during the lifetime of the project,
making quantitative assessment of area-at-risk and myocardial
salvage not feasible. Two of the patients did not have late gado-
linium CMR imaging (one in the culprit-only PCI group and
one in the preventive PCI group). Measurement of cardiac bio-
markers (eg, serial troponin testing) was not part of the PRAMI
trial protocol. There was heterogeneity in the duration of
follow-up due to logistical reasons.
CONCLUSIONS
We have performed an exploratory CMR substudy in the
PRAMI participants. We conclude that the beneﬁt from a pre-
ventive PCI strategy was unrelated to infarct size or LV remodel-
ling, although the strength of this conclusion is tempered by the
fact that study was underpowered to detect differences in these
parameters. Further studies are required.
Key messages
What is already known on this subject?
Percutaneous coronary intervention (PCI) in patients with acute
ST-elevation myocardial infarction (STEMI) and multivessel
coronary disease is associated with improved clinical outcomes.
However, doubt remains about the beneﬁt of preventative PCI
of other coronary arteries in addition to culprit vessel
revascularisation.
What might this study add?
In this preventive angioplasty in myocardial infarction (PRAMI)
cardiac magnetic resonance substudy, compared with
culprit-only percutaneous coronary intervention (PCI), immediate
preventive PCI of additional vessels was associated with a low
incidence of iatrogenic myocardial infarction (n, %
(culprit-artery-only PCI vs preventive PCI), 0 (0) vs 2 (5), p=0.15)
with no difference at follow-up in left ventricular (LV) ejection
fraction or LV volumes.
How might this impact on clinical practice?
A routine strategy of immediate preventive percutaneous
coronary intervention is a reasonable approach in selected
patients with acute ST-elevation myocardial infarction and
multivessel coronary disease.
Acknowledgements We thank the staff and patients who participated in this
study. We thank the National Health Service for supporting the costs of the CMR
scans. We thank Dr Christie McComb for letting us use her image quality
assessment system. We also thank Dr Craig Buckley, Mr Peter Weale and Mr Patrick
Revell, Siemens Healthcare, Frimley, UK, who provided technical support. We thank
the R&D Department of the Golden Jubilee National Hospital for supporting this
study.
Mangion K, et al. Heart 2016;0:1–8. doi:10.1136/heartjnl-2015-308660 7
Coronary artery disease
group.bmj.com on August 10, 2016 - Published by http://heart.bmj.com/Downloaded from 
Contributors CB and KGO made substantial contributions to conception and
design. DC, ARP, MM, RD, RW, RJE, MCP, MMcE, HE, KGO and CB made
substantial contributions to acquisition of data. KM, BWH, JMcC, KGO and CB
made substantial contributions to the analysis and interpretation of data. KM, KGO
and CB drafted the article. All authors were involved in revising it critically for
important intellectual content. All authors gave ﬁnal approval of the version to be
submitted and any revised version. CB is responsible for the overall content as
guarantor.
Funding CB was supported by the Scottish Funding Council. KM is supported by a
Fellowship from the British Heart Foundation (FS/15/54/31639). BWH was supported
by British Heart Foundation Project Grant PG/14/97/31263. National Health Service
(Scotland) supported the costs of the CMR scans.
Competing interests CB holds a research agreement with Siemens Healthcare
through the University of Glasgow. Relationships with industry: The University of
Glasgow holds a research agreement with Siemens Healthcare
Ethics approval UK National Research Ethics Service.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Qarawani D, Nahir M, Abboud M, et al. Culprit only versus complete coronary
revascularization during primary PCI. Int J Cardiol 2008;123:288–92.
2 El-Hayek GE, Gershlick AH, Hong MK, et al. Meta-analysis of randomized controlled
trials comparing multivessel versus culprit-only revascularization for patients with
ST-segment elevation myocardial infarction and multivessel disease undergoing
primary percutaneous coronary intervention. Am J Cardiol 2015;115:1481–6.
3 Nienhuis MB, Ottervanger JP, Bilo HJG, et al. Prognostic value of troponin after
elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc
Interv 2008;71:318–24.
4 Testa L, Van Gaal WJ, Biondi Zoccai GGL, et al. Myocardial infarction after
percutaneous coronary intervention: a meta-analysis of troponin elevation applying
the new universal deﬁnition. QJM 2009;102:369–78.
5 Kong JA, Chou ET, Minutello RM, et al. Safety of single versus multi-vessel
angioplasty for patients with acute myocardial infarction and multi-vessel coronary
artery disease: report from the New York State Angioplasty Registry. Coron Artery
Dis 2006;17:71–5.
6 Cavender MA, Milford-Beland S, Roe MT, et al. Prevalence, predictors, and
in-hospital outcomes of non-infarct artery intervention during primary percutaneous
coronary intervention for ST-segment elevation myocardial infarction (from The
National Cardiovascular Data Registry). Am J Cardiol 2009;104:507–13.
7 Bainey KR, Mehta SR, Lai T, et al. Complete vs culprit-only revascularization for
patients with multivessel disease undergoing primary percutaneous coronary
intervention for ST-segment elevation myocardial infarction: a systematic review and
meta-analysis. Am Heart J 2014;167:1–14.e2.
8 Windecker S, Kolh P, Alfonso F, et al., Authors/Task Force members. 2014 ESC/
EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial
Revascularization of the European Society of Cardiology (ESC) and the European
Association for Cardio-Thoracic Surgery (EACTS) * Developed with the special
contribution of the European Association of Percutaneous Cardiovascular
Interventions (EAPCI). Eur Heart J 2014;35:2541–619.
9 Steg PG, James SK, Atar D, et al., Authors/Task Force Members. ESC Guidelines for
the management of acute myocardial infarction in patients presenting with
ST-segment elevation: the Task Force on the management of ST-segment elevation
acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J
2012;33:2569–619.
10 Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on
duration of dual antiplatelet therapy in patients with coronary artery disease: a report
of the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. J Am Coll Cardiol 2016;10; pii: S0735-1097(16)01699-5.
11 Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in
myocardial infarction. N Engl J Med 2013;369:1115–23.
12 Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus
lesion-only revascularization in patients undergoing primary percutaneous coronary
intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol
2015;65:963–72.
13 Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment
of the culprit lesion only in patients with ST-segment elevation myocardial infarction
and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised
controlled trial. Lancet 2015;386:665–71 (cited 10 August 2015). http://www.
sciencedirect.com/science/article/pii/S0140673615606481
14 McCann GP, Khan JN, Greenwood JP, et al. Complete versus lesion-only primary
PCI: the randomized cardiovascular MR CvLPRIT substudy. J Am Coll Cardiol
2015;66:2713–24.
15 La Gerche A, Claessen G, Van de Bruaene A, et al. Cardiac MRI: a new gold
standard for ventricular volume quantiﬁcation during high-intensity exercise. Circ
Cardiovasc Imaging 2013;6:329–38.
16 Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection
fraction and volumes in heart failure by echocardiography, radionuclide
ventriculography and cardiovascular magnetic resonance; are they interchangeable?
Eur Heart J 2000;21:1387–96.
17 Aletras AH, Kellman P, Derbyshire JA, et al. ACUT2E TSE-SSFP: a hybrid method
for T2-weighted imaging of edema in the heart. Magn Reson Med
2008;59:229–35.
18 Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group randomised trials. BMJ
2010;340:c869.
19 Tarantini G, Napodano M, Gasparetto N, et al. Impact of multivessel coronary artery
disease on early ischemic injury, late clinical outcome, and remodeling in patients
with acute myocardial infarction treated by primary coronary angioplasty. Coron
Artery Dis 2010;21:78–86.
20 Burke SW, Solomon AJ. Cardiac complications of end-stage renal disease. Adv Ren
Replace Ther 2000;7:210–19.
21 McKechnie RS, Smith D, Montoye C, et al. Prognostic implication of anemia on
in-hospital outcomes after percutaneous coronary intervention.
Circulation2004;110:271–7.
22 Gurm HS, Bhatt DL, Gupta R, et al. Preprocedural White blood cell count
and death after percutaneous coronary intervention. Am Heart J 2003;
146:692–8.
23 Alcock RF, Roy P, Adorini K, et al. Incidence and determinants of myocardial
infarction following percutaneous coronary interventions according to the revised
Joint Task Force deﬁnition of troponin T elevation. Int J Cardiol
2010;140:66–72.
24 Rahimi K, Banning AP, Cheng ASH, et al. Prognostic value of coronary
revascularisation-related myocardial injury: a cardiac magnetic resonance imaging
study. Heart 2009;95:1937–43.
25 Carrick D, Haig C, Ahmed N, et al. Myocardial hemorrhage after acute
reperfused ST-segment-elevation myocardial infarction: relation to
microvascular obstruction and prognostic signiﬁcance. Circ Cardiovasc Imaging
2016;9:e004148.
26 Eitel I, Wöhrle J, Suenkel H, et al. Intracoronary compared with intravenous bolus
abciximab application during primary percutaneous coronary intervention in
ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of
the AIDA STEMI trial. J Am Coll Cardiol 2013;61:1447–54.
27 Carrick D, Berry C. Prognostic importance of myocardial infarct characteristics. Eur
Heart J Cardiovasc Imaging 2013;14:313–15.
28 de Waha S, Desch S, Eitel I, et al. Relationship and prognostic value of
microvascular obstruction and infarct size in ST-elevation myocardial infarction
as visualized by magnetic resonance imaging. Clin Res Cardiol
2012;101:487–95.
29 Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After
Primary PCI for STEMI—Full Text View—ClinicalTrials.gov. (cited 11 March 2015).
https://clinicaltrials.gov/ct2/show/NCT01740479
30 Comparison Between FFR Guided Revascularization Versus Conventional Strategy in
Acute STEMI Patients With MVD.—Full Text View—ClinicalTrials.gov. (cited 11
March 2015). https://clinicaltrials.gov/ct2/show/NCT01399736
8 Mangion K, et al. Heart 2016;0:1–8. doi:10.1136/heartjnl-2015-308660
Coronary artery disease
group.bmj.com on August 10, 2016 - Published by http://heart.bmj.com/Downloaded from 
intervention
after preventive percutaneous coronary 
Infarct size and left ventricular remodelling
Oldroyd and Colin Berry
Edwards, Mark C Petrie, Margaret McEntegart, Hany Eteiba, Keith G
John McClure, Maureen Mason, Rajiv Das, Rebecca Wilson, Richard J 
Kenneth Mangion, David Carrick, Barry W Hennigan, Alexander R Payne,
 published online August 8, 2016Heart 
 http://heart.bmj.com/content/early/2016/08/08/heartjnl-2015-308660
Updated information and services can be found at: 
These include:
References
 #BIBL
http://heart.bmj.com/content/early/2016/08/08/heartjnl-2015-308660
This article cites 27 articles, 12 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (184)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on August 10, 2016 - Published by http://heart.bmj.com/Downloaded from 
